Osiris Therapeutics, Inc. Cleared By FDA To Begin Phase II Stem Cell Trial For The Treatment Of Crohn’s Disease

BALTIMORE--(BUSINESS WIRE)--Dec. 8, 2005--Osiris Therapeutics, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin enrollment in a Phase II clinical trial to evaluate the safety and effectiveness of PROCHYMAL(TM) for the treatment of Crohn’s Disease. With the launch of this program, Osiris now has five active clinical trials evaluating its proprietary stem cell drugs in autoimmune, oncology, cardiac and orthopedic indications.

MORE ON THIS TOPIC